Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine 2001 March;45(1) > The Quarterly Journal of Nuclear Medicine 2001 March;45(1):84-90

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

  NUCLEAR MEDICINE APPLICATIONS FOR BONE METASTASES 

The Quarterly Journal of Nuclear Medicine 2001 March;45(1):84-90

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

186Re-Etidronate. Efficacy of palliative radionuclide therapy for painful bone metastases

Han S. H., De Klerk J. M. H., Zonnenberg B. A., Tan S., Van Rijk P. P.

From the Department of Nuclear Medicine *Oncology Section, Department of Internal Medicine, University Medical Center Utrecht, The Netherlands


PDF


Pain pal­li­a­tion ­with ­bone-seek­ing radio­phar­ma­ceu­ti­cals is an effec­tive treat­ment modal­ity in ­patients ­with ­advanced met­a­stat­ic ­bone can­cer. Several stud­ies ­have ­shown encour­ag­ing clin­i­cal ­results of pal­li­a­tive ther­a­py ­using 186Re-­HEDP, ­with an over­all report­ed ­response ­rate of ±71% for pain­ful ­osseous metas­ta­sized pros­tate and ­breast can­cer ­patients. 186Re-­HEDP is a ­very poten­tial iso­tope ­with numer­ous advan­ta­geous char­ac­ter­is­tics for ­this pur­pose. Myelosuppressive tox­ic­ity is lim­it­ed and rever­sible, ­which ­makes repet­i­tive treat­ment ­safe. However, indi­vid­u­al stud­ies are dif­fi­cult to com­pare, and are ham­pered by the numer­ous and dif­fer­ent meth­ods ­used to ­assess clin­i­cal ­respons. Standardized clin­i­cal ­response assess­ment ­using the objec­tive mul­ti-dimen­sion­al ­pain eval­u­a­tion mod­el ­should there­fore be imple­ment­ed.

top of page